Navigation Links
FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
Date:10/15/2007

eumoniae, P. mirabilis, P. aeruginosa, or A. baumannii.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX and other antibacterial drugs, DORIBAX should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting and modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

IMPORTANT SAFETY INFORMATION

DORIBAX is contraindicated in patients with known serious hypersensitivity to doripenem or other carbapenems or in patients who have demonstrated anaphylactic reactions to beta-lactams.

Serious and occasionally fatal hypersensitivity (anaphylactic) and serious skin reactions have been reported in patients receiving beta-lactam antibiotics. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens. If an allergic reaction to DORIBAX occurs, discontinue the drug. Serious acute anaphylactic reactions require emergency treatment with epinephrine and other emergency measures, including oxygen, IV fluids, IV antihistamines, corticosteroids, pressor amines and airway management, as clinically indicated.

Carbapenems may reduce serum valproic acid concentrations to subtherapeutic levels, resulting in loss of seizure control. Serum valproic acid concentrations should be monitored frequently after initiating carbapenem therapy. Alternative antibacterial or anticonvulsant therapy should be considered if serum valproic acid concentrations cannot be maintained in the therapeutic range or seizures occur.

Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. CDAD must be considered in all pati
'/>"/>

SOURCE Ortho-McNeil, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. UW Board of Regents approves $134 million medical research facility
7. FDA approves Bone Cares Hectorol for treatment of kidney disease
8. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
9. Improve Recovery and Reproducibility with Pre-Treatment of Analytical TSK-GEL G3000SWXL Size Exclusion Columns
10. Quintessence cancer treatment chosen for clinical studies
11. ZyStor to exhibit cell disorder treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)...  Schulman Associates IRB, Inc., the industry-leading central IRB ... lease on Laboratory Drive in the heart of ... location will house review board and service staff, which ... and customer service to clients. CBRE ... the deal, while Capital Associates Management, LLC represented the ...
(Date:4/16/2015)... The Council for Agricultural Science and ... CAST Communication Award goes to Dr. Channapatna Prakash, ... Alabama. Award nominees must demonstrate an ability to ... use of television, radio, or other social media. ... specialist in the field of plant genetics and ...
(Date:4/16/2015)... , April 16, 2015 /CNW/ - Bioenterprise Corporation is pleased ... office in Charlottetown , PEI.  Bioenterprise ... Edward Island ADAPT Council for the commercialization of agricultural ... to working with PEI ADAPT.  They have been at ... than a decade," explains Dave Smardon , President ...
(Date:4/16/2015)... , April 16, 2015  Scientists from Cleave Biosciences ... on the Horizon," at the American Association for Cancer ... on Sunday, April 19, 2015 from 3:15pm ... Director of Biology, will present new in vivo and ... oral inhibitor of p97, a critical enzyme that controls ...
Breaking Biology Technology:Schulman IRB to Open Office in Research Triangle Park, N.C. 2The 2015 Borlaug CAST Communication Award Goes to Channapatna Prakash 2Bioenterprise Corporation Expands into the Maritimes 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3
... Other important parameters for optimizing electroporation., , , , , , , ... , Pulse length , , ... Adjustment , of the electroporation buffer , ... Influence , of temperature , Influence ...
... , , , , ... , to degradation than DNA. Unlike Deoxyribonucleases (DNases), ... can therefore easily be inactivated with chelating , ... requirements and advantage of the 2 hydroxyl groups adjacent to ...
... How can Brinkmann TM Help ? , , , , , ... , , ... laboratory technique that is performed everyday, for a good portion , ... Due to the nature of the tests being conducted, only short breaks , ...
Cached Biology Technology:Optimizing electroporation parameters 2Optimizing electroporation parameters 3Optimizing electroporation parameters 4Optimizing electroporation parameters 5Decontamination and inhibition of ribonucleases 2Decontamination and inhibition of ribonucleases 3Decontamination and inhibition of ribonucleases 4Ergonomics and Liquid Handling, How can BrinkmannTM Help ? 2Ergonomics and Liquid Handling, How can BrinkmannTM Help ? 3Ergonomics and Liquid Handling, How can BrinkmannTM Help ? 4
(Date:4/2/2015)... 2, 2015 According to preliminary ... to somewhat higher than 125 MSEK. This exceeds the ... 2014 that revenues for Q1 2015 would be in ... for Q4 2014. The operating result for the first ... complete interim report will as previously communicated be published ...
(Date:3/31/2015)... -- Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant Talk" ... Network Architecture (ET Software DNA® 2.0) platforms and cyber ... million for the year ended December 31, 2014 as ... ended December 31, 2013. At the ... multi-year transition away from its legacy landline business to ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... are significantly more open to the idea of "designing" babies ... psychologists at the University of East Anglia. , The findings ... Festival of Science on Setpember 5. , Dr. Hampton and ... Studies examined what different groups of people in the UK ...
... that influences several aspects of nicotine-induced behaviors in the ... Drug Abuse, was presented today at the American College ... PhD, associate professor of psychiatry and her colleagues at ... a molecule called CREB in a brain area called ...
... In a finding that broadens our understanding of ... risk when crossing roads and draw on an ... primates--of protective "socio-spatial" organization that produces flexible, adaptive, ... facing risk. The research is reported by Kimberley ...
Cached Biology News:Designer babies - what would you do for a 'healthy' baby? 2New research identifies gene important for nicotine's effects on the brain 2Road-crossing in chimpanzees: A risky business 2
Performance, mycoplasma, virus, and endotoxin tested...
... Gel Loading Buffer is ... and tracking of DNA ... native polyacrylamide gels. This ... density sucrose which allows ...
... Cloning is the most ... cloning PCR products. TOPO ... Blunt TOPO vectors are ... with topoisomerase I. This ...
ready-to-use solution...
Biology Products: